Monovalent IgG4 molecules

References

• Pavlou AK, Belsey MJ. The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 2005; 59:389 - 96; http://dx.doi.org/10.1016/j.ejpb.2004.11.007; PMID: 15760719
   PubMed Web of Science ®Google Scholar
• Parren PW, van de Winkel JG. An integrated science-based approach to drug development. Curr Opin Immunol 2008; 20:426 - 30; http://dx.doi.org/10.1016/j.coi.2008.06.006; PMID: 18602995
   PubMed Web of Science ®Google Scholar
• Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9:423 - 30; http://dx.doi.org/10.2174/138920108786786358; PMID: 19075682
   PubMed Web of Science ®Google Scholar
• Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7:1401 - 13; http://dx.doi.org/10.1517/14712598.7.9.1401; PMID: 17727329
   PubMed Web of Science ®Google Scholar
• Salfeld JG. Isotype selection in antibody engineering. Nat Biotechnol 2007; 25:1369 - 72; http://dx.doi.org/10.1038/nbt1207-1369; PMID: 18066027
   PubMed Web of Science ®Google Scholar
• Pacchiana G, Chiriaco C, Stella MC, Petronzelli F, De Santis R, Galluzzo M, et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem 2010; 285:36149 - 57; http://dx.doi.org/10.1074/jbc.M110.134031; PMID: 20833723
   PubMed Web of Science ®Google Scholar
• O’Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, et al. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 2006; 66:9162 - 70; http://dx.doi.org/10.1158/0008-5472.CAN-06-0283; PMID: 16982759
   PubMed Web of Science ®Google Scholar
• Brekke OH, Løset GA. New technologies in therapeutic antibody development. Curr Opin Pharmacol 2003; 3:544 - 50; http://dx.doi.org/10.1016/j.coph.2003.05.002; PMID: 14559101
   PubMed Web of Science ®Google Scholar
• Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009; 157:220 - 33; http://dx.doi.org/10.1111/j.1476-5381.2009.00190.x; PMID: 19459844
   PubMed Web of Science ®Google Scholar
• Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 1996; 26:690 - 6; http://dx.doi.org/10.1002/eji.1830260327; PMID: 8605939
   PubMed Web of Science ®Google Scholar
• Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 1996; 89:573 - 8; http://dx.doi.org/10.1046/j.1365-2567.1996.d01-775.x; PMID: 9014824
   PubMed Web of Science ®Google Scholar
• Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A 1996; 93:5512 - 6; http://dx.doi.org/10.1073/pnas.93.11.5512; PMID: 8643606
   PubMed Web of Science ®Google Scholar
• Martin WL, West AP Jr., Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell 2001; 7:867 - 77; http://dx.doi.org/10.1016/S1097-2765(01)00230-1; PMID: 11336709
   PubMed Web of Science ®Google Scholar
• Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83:253 - 307; PMID: 12506131
   PubMed Web of Science ®Google Scholar
• Wartiovaara J, Ofverstedt LG, Khoshnoodi J, Zhang J, Mäkelä E, Sandin S, et al. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J Clin Invest 2004; 114:1475 - 83; PMID: 15545998
   PubMed Web of Science ®Google Scholar
• Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008; 60:1421 - 34; http://dx.doi.org/10.1016/j.addr.2008.04.012; PMID: 18541331
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767 - 71; http://dx.doi.org/10.1038/nbt.1553; PMID: 19620983
   PubMed Web of Science ®Google Scholar
• van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554 - 7; http://dx.doi.org/10.1126/science.1144603; PMID: 17872445
   PubMed Web of Science ®Google Scholar
• Rose RJ, Labrijn AF, van den Bremer ET, Loverix S, Lasters I, van Berkel PH, et al. Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure 2011; 19:1274 - 82; http://dx.doi.org/10.1016/j.str.2011.06.016; PMID: 21893287
   PubMed Web of Science ®Google Scholar
• Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 1993; 30:105 - 8; http://dx.doi.org/10.1016/0161-5890(93)90432-B; PMID: 8417368
   PubMed Web of Science ®Google Scholar
• Bloom JW, Madanat MS, Marriott D, Wong T, Chan SY. Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci 1997; 6:407 - 15; http://dx.doi.org/10.1002/pro.5560060217; PMID: 9041643
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Rispens T, Meesters J, Rose RJ, den Bleker TH, Loverix S, et al. Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol 2011; 187:3238 - 46; http://dx.doi.org/10.4049/jimmunol.1003336; PMID: 21841137
   PubMed Web of Science ®Google Scholar
• Schuurman J, Perdok GJ, Gorter AD, Aalberse RC. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 2001; 38:1 - 8; http://dx.doi.org/10.1016/S0161-5890(01)00050-5; PMID: 11483205
   PubMed Web of Science ®Google Scholar
• Peters SJ, Smales CM, Henry AJ, Stephens PE, West S, Humphreys DP. Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability. J Biol Chem 2012; 287:24525 - 33; http://dx.doi.org/10.1074/jbc.M112.369744; PMID: 22610095
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Loverix S, Parren PW, Van de Winkel JG, Schuurman J, Lasters I. Antibody variants having modifications in the constant region. 2008; WO 2010/063785.
   Google Scholar
• Parren PW, Schuurman J, Vink T, Bleeker WK, Van de Winkel JG, Van Berkel PH, et al. Recombinant monovalent antibodies and methods for production thereof. 2006; PCT/DK2006/000669:WO 2007/059782.
   Google Scholar
• Zhou H, Kannan G, Sun N. Monomeric antibody fc. 2009; PCT/US2010/057662:WO 2011/063348 A1.
   Google Scholar
• Ying TL, Chen WZ, Gong R, Feng Y, Dimitrov DS. Soluble monomeric IgG1 fc. J Biol Chem 2012; 287:19399 - 408; http://dx.doi.org/10.1074/jbc.M112.368647; PMID: 22518843
   PubMed Web of Science ®Google Scholar
• Dall’Acqua W, Simon AL, Mulkerrin MG, Carter P. Contribution of domain interface residues to the stability of antibody CH3 domain homodimers. Biochemistry 1998; 37:9266 - 73; http://dx.doi.org/10.1021/bi980270i; PMID: 9649307
   PubMed Web of Science ®Google Scholar
• Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 1981; 20:2361 - 70; http://dx.doi.org/10.1021/bi00512a001; PMID: 7236608
   PubMed Web of Science ®Google Scholar
• Miller S. Protein-protein recognition and the association of immunoglobulin constant domains. J Mol Biol 1990; 216:965 - 73; http://dx.doi.org/10.1016/S0022-2836(99)80014-X; PMID: 2125082
   PubMed Web of Science ®Google Scholar
• Teerinen T, Valjakka J, Rouvinen J, Takkinen K. Structure-based stability engineering of the mouse IgG1 Fab fragment by modifying constant domains. J Mol Biol 2006; 361:687 - 97; http://dx.doi.org/10.1016/j.jmb.2006.06.073; PMID: 16876195
   PubMed Web of Science ®Google Scholar
• Stafford WF, Sherwood PJ. Analysis of heterologous interacting systems by sedimentation velocity: curve fitting algorithms for estimation of sedimentation coefficients, equilibrium and kinetic constants. Biophys Chem 2004; 108:231 - 43; http://dx.doi.org/10.1016/j.bpc.2003.10.028; PMID: 15043932
   PubMed Web of Science ®Google Scholar
• Rai N, Nöllmann M, Spotorno B, Tassara G, Byron O, Rocco M. SOMO (SOlution MOdeler) differences between X-Ray- and NMR-derived bead models suggest a role for side chain flexibility in protein hydrodynamics. Structure 2005; 13:723 - 34; http://dx.doi.org/10.1016/j.str.2005.02.012; PMID: 15893663
   PubMed Web of Science ®Google Scholar
• Laue TM, Shah BD, Ridegway TM, Pelletier SL. Computer-aided interpretation of analytical sedimentation data for proteins. In: Harding SE, Rowe AJ, Horton JC, eds. Ultracentrifugation in Biochemistry and Polymer Science: Royal Soceity of Chemistry, Cambridge, 1992:90-125.
   Google Scholar
• Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 2000; 37:697 - 706; http://dx.doi.org/10.1016/S0161-5890(00)00105-X; PMID: 11275255
   PubMed Web of Science ®Google Scholar
• Vermeer AW, Norde W. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. Biophys J 2000; 78:394 - 404; http://dx.doi.org/10.1016/S0006-3495(00)76602-1; PMID: 10620303
   PubMed Web of Science ®Google Scholar
• Rispens T, den Bleker TH, Aalberse RC. Hybrid IgG4/IgG4 Fc antibodies form upon ‘Fab-arm’ exchange as demonstrated by SDS-PAGE or size-exclusion chromatography. Mol Immunol 2010; 47:1592 - 4; http://dx.doi.org/10.1016/j.molimm.2010.02.021; PMID: 20299101
   PubMed Web of Science ®Google Scholar
• Rispens T, Ooijevaar-de Heer P, Bende O, Aalberse RC. Mechanism of immunoglobulin G4 Fab-arm exchange. J Am Chem Soc 2011; 133:10302 - 11; http://dx.doi.org/10.1021/ja203638y; PMID: 21627172
   PubMed Web of Science ®Google Scholar
• Martin WL, Bjorkman PJ. Characterization of the 2:1 complex between the class I MHC-related Fc receptor and its Fc ligand in solution. Biochemistry 1999; 38:12639 - 47; http://dx.doi.org/10.1021/bi9913505; PMID: 10504233
   PubMed Web of Science ®Google Scholar
• Raghavan M, Wang Y, Bjorkman PJ. Effects of receptor dimerization on the interaction between the class I major histocompatibility complex-related Fc receptor and IgG. Proc Natl Acad Sci U S A 1995; 92:11200 - 4; http://dx.doi.org/10.1073/pnas.92.24.11200; PMID: 7479965
   PubMed Web of Science ®Google Scholar
• Vaughn DE, Bjorkman PJ. High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization. Biochemistry 1997; 36:9374 - 80; http://dx.doi.org/10.1021/bi970841r; PMID: 9235980
   PubMed Web of Science ®Google Scholar
• Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999; 17:780 - 3; http://dx.doi.org/10.1038/11717; PMID: 10429243
   PubMed Web of Science ®Google Scholar
• Nguyen A, Reyes AE 2nd, Zhang M, McDonald P, Wong WL, Damico LA, et al. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 2006; 19:291 - 7; http://dx.doi.org/10.1093/protein/gzl011; PMID: 16621915
   PubMed Web of Science ®Google Scholar
• Pepinsky RB, Walus L, Shao Z, Ji B, Gu S, Sun Y, et al. Production of a PEGylated Fab’ of the anti-LINGO-1 Li33 antibody and assessment of its biochemical and functional properties in vitro and in a rat model of remyelination. Bioconjug Chem 2011; 22:200 - 10; http://dx.doi.org/10.1021/bc1002746; PMID: 21254764
   PubMed Web of Science ®Google Scholar
• Valentine JL, Arnold LW, Owens SM. Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats. J Pharmacol Exp Ther 1994; 269:1079 - 85; PMID: 8014850
   PubMed Web of Science ®Google Scholar
• Kim JK, Tsen MF, Ghetie V, Ward ES. Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur J Immunol 1994; 24:2429 - 34; http://dx.doi.org/10.1002/eji.1830241025; PMID: 7925571
   PubMed Web of Science ®Google Scholar
• Tesar DB, Tiangco NE, Bjorkman PJ. Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor. Traffic 2006; 7:1127 - 42; http://dx.doi.org/10.1111/j.1600-0854.2006.00457.x; PMID: 17004319
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514 - 24; http://dx.doi.org/10.1074/jbc.M604292200; PMID: 16793771
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002; 169:5171 - 80; PMID: 12391234
   PubMed Web of Science ®Google Scholar
• Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003; 325:979 - 89; http://dx.doi.org/10.1016/S0022-2836(02)01250-0; PMID: 12527303
   PubMed Web of Science ®Google Scholar
• Corper AL, Sohi MK, Bonagura VR, Steinitz M, Jefferis R, Feinstein A, et al. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol 1997; 4:374 - 81; http://dx.doi.org/10.1038/nsb0597-374; PMID: 9145108
   PubMedGoogle Scholar
• DeLano WL. The PyMOL User's Manual. DeLano Scientific, Palo Alto, Ca, USA: 2002.
   Google Scholar
• Tsai CJ, Lin SL, Wolfson HJ, Nussinov R. A dataset of protein-protein interfaces generated with a sequence-order-independent comparison technique. J Mol Biol 1996; 260:604 - 20; http://dx.doi.org/10.1006/jmbi.1996.0424; PMID: 8759323
   PubMed Web of Science ®Google Scholar
• Andrews PR, Craik DJ, Martin JL. Functional group contributions to drug-receptor interactions. J Med Chem 1984; 27:1648 - 57; http://dx.doi.org/10.1021/jm00378a021; PMID: 6094812
   PubMed Web of Science ®Google Scholar
• Carver F, Hunter C, Seward E. Structure-activity relationship for quantifying aromatic interactions. Chem Commun 1998; 775 - 6; http://dx.doi.org/10.1039/a800567b
   Web of Science ®Google Scholar
• Persic L, Roberts A, Wilton J, Cattaneo A, Bradbury A, Hoogenboom HR. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 1997; 187:9 - 18; http://dx.doi.org/10.1016/S0378-1119(96)00628-2; PMID: 9073061
   PubMed Web of Science ®Google Scholar
• Chodorge M, Züger S, Stirnimann C, Briand C, Jermutus L, Grütter MG, et al. A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell Death Differ 2012; 19:1187 - 95; http://dx.doi.org/10.1038/cdd.2011.208; PMID: 22261618
   PubMed Web of Science ®Google Scholar
• Laurent TC, Killander J. A theory of gel filtration and its exeperimental verification. J Chromatogr A 1964; 14:317 - 30; http://dx.doi.org/10.1016/S0021-9673(00)86637-6
   Web of Science ®Google Scholar
• Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J 2000; 78:1606 - 19; http://dx.doi.org/10.1016/S0006-3495(00)76713-0; PMID: 10692345
   PubMed Web of Science ®Google Scholar
• Sali A, Potterton L, Yuan F, van Vlijmen H, Karplus M. Evaluation of comparative protein modeling by MODELLER. Proteins 1995; 23:318 - 26; http://dx.doi.org/10.1002/prot.340230306; PMID: 8710825
   PubMed Web of Science ®Google Scholar